Clinical Trials Directory

Trials / Completed

CompletedNCT06329284

Midkine Role With Deregulated Oxidative and Immune Milieu in Induction of Preeclampsia

Midkine Interplays With Oxidative Stress and Inflammatory Milieu to Induce Preeclampsia in Normotensive Pregnant Women

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
80 (actual)
Sponsor
Benha University · Academic / Other
Sex
Female
Age
21 Years – 50 Years
Healthy volunteers
Accepted

Summary

Preeclampsia (PE) is a hypertensive pregnancy-related disorder that endangers maternal and fetal outcomes and accounts for 9-10% of maternal mortalities with its early-onset phenotype is the most dangerous, but its etiology is still not fully elucidated. Midkine (MDK) is a multifunctional protein that plays a unique role in the development of hypertension (HTN), via its proatherogenic effect and induction of overexpression of angiotensin converting enzyme. Oxidative stress (OS) upregulates the expression of MDK and MDK induces propagation of neoangiogenesis and acts as chemotactic for neutrophils.

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTELISAELISA estimation of serum Midkine, tumor necrosis factor Alfa, superoxide dismutase, malondialdehyde, placental growth factor and placental soluble fms-like tyrosine kinase 1

Timeline

Start date
2023-01-01
Primary completion
2023-09-15
Completion
2023-12-15
First posted
2024-03-25
Last updated
2024-03-26

Locations

1 site across 1 country: Egypt

Source: ClinicalTrials.gov record NCT06329284. Inclusion in this directory is not an endorsement.